Cardiology

A systematic review of over 400 studies in type 2 diabetes reveals 13 biomarkers, including NT-proBNP and troponin-t, with potential to significantly enhance cardiovascular disease risk prediction.

A new study found the periodic limb movement index, but not the apnea-hypopnea index, was linked to an increased risk of incident cardiovascular disease or death every 10 events per hour.

In a study involving over 500 children, artificial intelligence using echocardiography demonstrated accuracy comparable to expert cardiologists in detecting rheumatic heart disease, hinting at the prospect of a potentially transformative tool for early intervention and disease prevention.

A new study found behavioral activation therapy is just as effective as antidepressants for treating depressive symptoms in patients with heart failure, with both treatments having a 50% reduction at months 3, 6, and 12.

Compared to the usual care, patients with HFpEF in the active arms demonstrated less improvement in peakVO2 when they had iron deficiency and lower values of ferritin and transferrin saturation, according to a new study.

On January 25, 2024, the day following the proposed PDUFA goal date, Liquidia Corporation announced the FDA was still reviewing the NDA for pulmonary hypertension with interstitial lung disease for treprostinil inhalation powder (Yutrepia).

Addressing isolation and loneliness indexes resulted in a decreased risk of all-cause mortality among individuals with obesity in the UK Biobank.

The American Heart Association's annual report on heart disease and stroke statistics for 2024 sheds new light on the impact and level of public education surrounding the impact of heart disease and stroke in the US and abroad.

Childhood trauma may decrease the likelihood of optimal heart health in adulthood, while stable and nurturing experiences are shown to promote heart health.

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.

An analysis of the RAFT trial showed patients with heart failure treated with CRT-D experienced continued survival benefits during a median of nearly 14 years of follow-up.

Prescribing phosphodiesterase type 5 inhibitors and nitrates together may increase the risk of morbidity and mortality for patients over time.

This cardiology case report from Brady Pregerson, MD, features a man in his early 60s with no known medical history presenting with chest pain radiating to both armpits and anterior neck, but not to the back. How would you react?

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

A multidisciplinary panel assembled by the Society for Cardiovascular Angiography & Interventions examined and supported the role of intravascular ultrasounds in lower extremity revascularization procedures.

Randomized trial data shows colchicine administered following catheter ablation did not reduce atrial arrhythmia recurrence or associated clinical events.

Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.

Applied Therapeutics announced topline results from ARISE-HF on January 04, 2023 and plans to present full results at an upcoming medical conference.

A new study identified T1D as a risk factor associated with nearly all subtypes of CHD, whereas overweight was associated only with certain defect types.

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Our cardiology month in review spotlights our most popular cardiology-centric content from the month of December 2023. The list includes topline data from SEQUOIA-HCM, new data on the impact of structural racism on chronic health conditions, and more!

Post hoc analysis of STRONG-HF trial underscores benefits of higher guideline-directed medical therapy doses in acute heart failure, showing lower rates of death or readmission at 6 months with more rapid uptitration.

On December 27, 2023, Cytokinetics announced positive topline results from the phase 3 SEQUOIA-HCM trial evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

This cardiology case report from Brady Pregerson, MD, features a man in his mid-30s brought by ambulance after 3-4 days of peripheral edema and generalized weakness after a missed dialysis appointment. Can you determine the correct diagnosis?

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

Sex-based differences in hypertrophic cardiomyopathy outcomes reveal higher risks for women, including all-cause mortality.